Utilizing a range of high-content and high-throughput screening approaches specifically designed to target TDP-43 proteinopathy, researchers are now exploring potential compounds from extensive libraries, including tens of thousands of natural products, small molecular entities, and FDA-approved drugs. This evidence concerns the gene TARDBP and proteostasis deficiencies.